Recently, prostatic acid phosphatase, polyadenosine-diphosphate-ribose polymerase (PARP), prostate-specific membrane antigen, and programmed cell death protein 1 (PD1) targeting therapies have been approved for certain forms of metastatic prostate cancer [2–4]. This evidence concerns the gene PDCD1 and metastatic prostate carcinoma.